Strategic Collaborations Propel Cell Therapy Advancements
In a significant stride towards enhancing cell therapy accessibility and efficacy, Be the Match BioTherapies® and Cryoport have announced a strategic partnership. IntegriTMCell, a revolutionary solution to bioprocessing, cryopreservation and distribution in the global cell therapy market, has been launched as part of this collaboration. IntegriTMCell is exceptionally placed to support the various production models, thus enhancing patient access to life changing therapies, thanks to state-of-the-art facilities in both the United States and the European Union.
Optimizing Cellular Starting Material for Improved Clinical Outcomes
The IntegriCellTM technology addresses a longstanding challenge in cell and gene therapy development variability of the beginning materials. Using standard bioprocessing and cryopreservation protocols, this ingenious solution guarantees delivery of optimised cell precursors. In establishing new industry benchmarks, Mark Sawicki, President and Chief Executive Officer of Cryoport Systems Inc. stressed the transformative potential of such a partnership he recited this sentiment and noted the significant impact that IntegriCellTM has had on manufacturing yields and patients’ outcomes.
Expanding GMP-Compliant Offerings for Cell Therapy Developers
Charles River Laboratories International, Inc. has expanded its CliniPrimeâ„¢ suite by introducing CliniPrime Cryopreserved Leukopaks. Designed to meet regulatory standards for clinical trial development and commercial manufacturing, these products provide a reliable GMP-compliant cellular starting material source. By simplifying logistics and mitigating risks to the supply chain, CliniPrime Cryopreserved Lepakukos facilitates a smooth progression through the development cycle that supports faster clinical progress.
Driving Growth and Innovation in the Cell Cryopreservation Market
A pivotal moment in the development of the cell cryopreservation market has been marked by a partnership between Be Match BioTherapies and Cryoport, with Charles River Laboratories expanding its GMP compliant offering. The future holds promising prospects for enhanced therapeutic efficacy, improved patient outcomes, and continued growth in the field of cell and gene therapy, as industry leaders continue to innovate and collaborate.
Vantage market research projects substantial growth in the cell cryopreservation market, with a compound annual growth rate (CAGR) of 18.4% from 2023 to 2032. Leading industry players such as Thermo Fisher Scientific Inc., Merck KGaA, Sartorius AG, and PromoCell GmbH are instrumental in driving innovation and securing contracts within this dynamic landscape. Their relentless focus on new product development and strategic collaborations underscores their commitment to advancing the field of cell therapy and positioning it for sustained growth and success.
About Vantage Market Research:
We, at Vantage Market Research, provide
quantified B2B high quality research on more than 20,000 emerging markets, in turn, helping our clients map
out constellation of opportunities for their businesses. We, as a competitive intelligence market research
and consulting firm provide end to end solutions to our client enterprises to meet their crucial business
objectives. Our clientele base spans across 70% of Global Fortune 500 companies. The company provides high
quality data and market research services. The company serves various enterprises and clients in a wide
variety of industries. The company offers detailed reports on multiple industries including Chemical
Materials and Energy, Food and Beverages, Healthcare Technology, etc. The company’s experienced team of
Analysts, Researchers, and Consultants use proprietary data sources and numerous statistical tools and
techniques to gather and analyse information.
Interactive Market Intelligence
Proprietary data visualization for stakeholders
Market Share Distribution
Revenue Growth (USD Bn)
